Clinically, this uncertainty is critical, as approximately 29% of R/M HNSCC patients experience hyperprogression and rapid tumor progression (≥2-fold growth kinetics) following PD-1/PD-L1 blockade, often associated with regional recurrence and reduced progression-free survival (51). The gene discussed is CD274; the disease is neoplasm.